News

The Janssen Research & Development, LLC ("Janssen")-sponsored registration study demonstrated a 19 percent reduction in risk of death in this study population (median OS, 34.7 vs 30.3 months,

In the U.S., the Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for previously treated advanced melanoma and the Prescription Drug

Earlier, Merrimack entered into an exclusive license and collaboration agreement with Baxter International for MM-398 outside of the US and Taiwan. In May 2011, PharmaEngine licensed the development,

SB623 is an allogeneic cell product derived from bone marrow stromal cells isolated from healthy donors, and is currently being developed by SanBio. Compared to autologous cell therapy,

ILUVIEN 0.19mg is a sustained release intravitreal implant approved in the US for the treatment of DME in patients who have been previously treated with a course of

Fomepizole is marketed and distributed by Paladin Labs (Paladin) in Canada and is the standard treatment for ethylene glycol and methanol poisonings. In 2011, Paladin and Takeda entered

Harvoni is a combination of the NS5A inhibitor ledipasvir (LDV) 90mg and the nucleotide analog polymerase inhibitor sofosbuvir (SOF) 400mg. The European Commission, which has the authority to

The CHMP recommendation is for the use of Lymphoseek in imaging and intraoperative detection of sentinel lymph nodes draining a primary tumor in adult patients with breast cancer,

The approval is for nintedanib (Vargatef) in combination with docetaxel to treat adults with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumor